---
document_datetime: 2025-12-02 04:59:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/spravato.html
document_name: spravato.html
version: success
processing_time: 0.1247718
conversion_datetime: 2025-12-28 15:28:18.391126
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Spravato

[RSS](/en/individual-human-medicine.xml/67264)

##### Authorised

This medicine is authorised for use in the European Union

esketamine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Spravato](#news-on)
- [More information on Spravato](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Spravato is a medicine used to treat adults with major depression that is resistant to treatment. It is used in combination with an SSRI or SNRI medicine (other antidepressants) when at least two other treatments have failed.

Spravato contains the active substance esketamine.

Expand section

Collapse section

## How is Spravato used?

Spravato is available as a nasal spray to be used by the patient in a clinic or doctor's office, under the direct supervision of a healthcare professional.

The recommended starting dose is one or two sprays in each nostril (depending on the patient's age) on the first day. This is followed by 1, 2 or 3 sprays in each nostril twice a week for 4 weeks. Afterwards, if the patient's depression improves, Spravato should be used once a week for the next 4 weeks and then once every 1 or 2 weeks for at least 6 months.

Because Spravato can increase blood pressure, patients' blood pressure should be measured before and after using Spravato. Patients with serious respiratory or heart problems should only use Spravato where facilities for resuscitating patients are immediately available.

Spravato can only be obtained with a prescription and the decision to start treatment should be taken by a psychiatrist. For more information about using Spravato, see the package leaflet or contact your doctor or pharmacist.

## How does Spravato work?

The active substance in Spravato, esketamine, is an antidepressant. It acts on receptors (targets) in the brain for a substance called NMDA. NMDA regulates the transmission of signals between cells in brain areas involved in the regulation of mood. By acting on these NMDA receptors, esketamine can help improve the symptoms of depression.

## What benefits of Spravato have been shown in studies?

Studies in around 1,800 patients have shown that Spravato taken with an SSRI or SNRI relieves symptoms of treatment-resistant depression as measured using a standard scoring system known as MADRS.

In a 4-week study, MADRS symptoms scores improved by 3.5 points more in patients treated with Spravato (plus an SSRI or SNRI) than in those treated with placebo (also with an SSRI or SNRI), a difference that is considered clinically relevant. Similar improvements were achieved in two other short-term studies, although the results were not as robust. The results of the three studies taken together convincingly showed that, overall, Spravato was more effective than placebo.

In a fourth long-term study, Spravato was shown to be effective at preventing relapses of depression. The proportion of patients given Spravato (plus an SSRI or SNRI) who relapsed during the study was 27%, compared with 45% in the placebo group (also given an SSRI or SNRI). A fifth study lasting around 1 year showed that the benefits of Spravato (plus an SSRI or SNRI) were maintained long-term.

## What are the risks associated with Spravato?

The most common side effects with Spravato (which may affect up to 3 in 10 people) are dizziness, nausea (feeling sick), dissociation (feeling of being disconnected from physical surroundings and emotions), headache, sleepiness, vertigo (a spinning sensation), dysgeusia (taste disturbances), hypoaesthesia (reduced sense of touch) and vomiting. For the full list of side effects of Spravato, see the package leaflet.

Spravato must not be used in patients with weaknesses in blood vessel walls that might rupture if blood pressure goes up, patients who have had bleeding in the brain and patients who recently had a heart attack. For the full list of restrictions, see the package leaflet.

## Why is Spravato authorised in the EU?

Studies showed that Spravato, added to SSRI or SNRI antidepressants, improves symptoms of major depression that have not improved with other treatment, both in the short- and in the long-term. Furthermore, the safety of Spravato was considered acceptable and its side effects manageable.

Because of risk of patients misusing this medicine or becoming addicted to it, Spravato will only be available under a special prescription and must be taken under direct supervision of a healthcare professional. The European Medicines Agency concluded that with these restrictions in place the benefits of Spravato are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Spravato?

The company that markets Spravato will provide educational material for doctors and a guide for patients with important information about Spravato's side effects, its risks and how to use the medicine.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Spravato have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Spravato are continuously monitored. Side effects reported with Spravato are carefully evaluated and any necessary action taken to protect patients.

## Other information about Spravato

Spravato received a marketing authorisation valid throughout the EU on 18 December 2019.

Spravato : EPAR - Medicine overview

Reference Number: EMA/578240/2019

English (EN) (123.14 KB - PDF)

**First published:** 19/12/2019

[View](/en/documents/overview/spravato-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-500)

български (BG) (143.69 KB - PDF)

**First published:**

19/12/2019

[View](/bg/documents/overview/spravato-epar-medicine-overview_bg.pdf)

español (ES) (118.06 KB - PDF)

**First published:**

19/12/2019

[View](/es/documents/overview/spravato-epar-medicine-overview_es.pdf)

čeština (CS) (139.84 KB - PDF)

**First published:**

19/12/2019

[View](/cs/documents/overview/spravato-epar-medicine-overview_cs.pdf)

dansk (DA) (117.14 KB - PDF)

**First published:**

19/12/2019

[View](/da/documents/overview/spravato-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.23 KB - PDF)

**First published:**

19/12/2019

[View](/de/documents/overview/spravato-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.99 KB - PDF)

**First published:**

19/12/2019

[View](/et/documents/overview/spravato-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.51 KB - PDF)

**First published:**

19/12/2019

[View](/el/documents/overview/spravato-epar-medicine-overview_el.pdf)

français (FR) (119.64 KB - PDF)

**First published:**

19/12/2019

[View](/fr/documents/overview/spravato-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.35 KB - PDF)

**First published:**

19/12/2019

[View](/hr/documents/overview/spravato-epar-medicine-overview_hr.pdf)

italiano (IT) (116.76 KB - PDF)

**First published:**

19/12/2019

[View](/it/documents/overview/spravato-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (156.47 KB - PDF)

**First published:**

19/12/2019

[View](/lv/documents/overview/spravato-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.74 KB - PDF)

**First published:**

19/12/2019

[View](/lt/documents/overview/spravato-epar-medicine-overview_lt.pdf)

magyar (HU) (141.84 KB - PDF)

**First published:**

19/12/2019

[View](/hu/documents/overview/spravato-epar-medicine-overview_hu.pdf)

Malti (MT) (143.14 KB - PDF)

**First published:**

19/12/2019

[View](/mt/documents/overview/spravato-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.07 KB - PDF)

**First published:**

19/12/2019

[View](/nl/documents/overview/spravato-epar-medicine-overview_nl.pdf)

polski (PL) (143.07 KB - PDF)

**First published:**

19/12/2019

[View](/pl/documents/overview/spravato-epar-medicine-overview_pl.pdf)

português (PT) (118.93 KB - PDF)

**First published:**

19/12/2019

[View](/pt/documents/overview/spravato-epar-medicine-overview_pt.pdf)

română (RO) (138.73 KB - PDF)

**First published:**

19/12/2019

[View](/ro/documents/overview/spravato-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.61 KB - PDF)

**First published:**

19/12/2019

[View](/sk/documents/overview/spravato-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.73 KB - PDF)

**First published:**

19/12/2019

[View](/sl/documents/overview/spravato-epar-medicine-overview_sl.pdf)

Suomi (FI) (115.63 KB - PDF)

**First published:**

19/12/2019

[View](/fi/documents/overview/spravato-epar-medicine-overview_fi.pdf)

svenska (SV) (117.43 KB - PDF)

**First published:**

19/12/2019

[View](/sv/documents/overview/spravato-epar-medicine-overview_sv.pdf)

Spravato : EPAR - Risk-management-plan

English (EN) (1.2 MB - PDF)

**First published:** 29/02/2024

**Last updated:** 10/09/2025

[View](/en/documents/rmp/spravato-epar-risk-management-plan_en.pdf)

## Product information

Spravato : EPAR - Product Information

English (EN) (1.83 MB - PDF)

**First published:** 19/12/2019

**Last updated:** 23/01/2025

[View](/en/documents/product-information/spravato-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-664)

български (BG) (1.1 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/bg/documents/product-information/spravato-epar-product-information_bg.pdf)

español (ES) (1.48 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/es/documents/product-information/spravato-epar-product-information_es.pdf)

čeština (CS) (1.23 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/cs/documents/product-information/spravato-epar-product-information_cs.pdf)

dansk (DA) (1.49 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/da/documents/product-information/spravato-epar-product-information_da.pdf)

Deutsch (DE) (2.08 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/de/documents/product-information/spravato-epar-product-information_de.pdf)

eesti keel (ET) (1.31 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/et/documents/product-information/spravato-epar-product-information_et.pdf)

ελληνικά (EL) (1.4 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/el/documents/product-information/spravato-epar-product-information_el.pdf)

français (FR) (1.28 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/fr/documents/product-information/spravato-epar-product-information_fr.pdf)

hrvatski (HR) (1.34 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/hr/documents/product-information/spravato-epar-product-information_hr.pdf)

íslenska (IS) (1.38 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/is/documents/product-information/spravato-epar-product-information_is.pdf)

italiano (IT) (1.83 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/it/documents/product-information/spravato-epar-product-information_it.pdf)

latviešu valoda (LV) (1.66 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/lv/documents/product-information/spravato-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.38 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/lt/documents/product-information/spravato-epar-product-information_lt.pdf)

magyar (HU) (1.04 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/hu/documents/product-information/spravato-epar-product-information_hu.pdf)

Malti (MT) (1.74 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/mt/documents/product-information/spravato-epar-product-information_mt.pdf)

Nederlands (NL) (905.68 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/nl/documents/product-information/spravato-epar-product-information_nl.pdf)

norsk (NO) (1.37 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/no/documents/product-information/spravato-epar-product-information_no.pdf)

polski (PL) (1.51 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/pl/documents/product-information/spravato-epar-product-information_pl.pdf)

português (PT) (1.45 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/pt/documents/product-information/spravato-epar-product-information_pt.pdf)

română (RO) (1.41 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/ro/documents/product-information/spravato-epar-product-information_ro.pdf)

slovenčina (SK) (1.37 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/sk/documents/product-information/spravato-epar-product-information_sk.pdf)

slovenščina (SL) (1.52 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/sl/documents/product-information/spravato-epar-product-information_sl.pdf)

Suomi (FI) (1.2 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/fi/documents/product-information/spravato-epar-product-information_fi.pdf)

svenska (SV) (1.57 MB - PDF)

**First published:**

19/12/2019

**Last updated:**

23/01/2025

[View](/sv/documents/product-information/spravato-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010825/202403 12/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Spravato : EPAR - All Authorised presentations

English (EN) (35.26 KB - PDF)

**First published:** 19/12/2019

**Last updated:** 31/08/2022

[View](/en/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-635)

български (BG) (37.52 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/bg/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_bg.pdf)

español (ES) (34.38 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/es/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.29 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/cs/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.75 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/da/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (38.27 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/de/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (34.59 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/et/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.16 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/el/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_el.pdf)

français (FR) (35.37 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/fr/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (35.14 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/hr/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (36.67 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/is/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_is.pdf)

italiano (IT) (34.92 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/it/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.43 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/lv/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.4 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/lt/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.61 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/hu/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.01 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/mt/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (35.9 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/nl/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (36.42 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/no/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.28 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/pl/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_pl.pdf)

português (PT) (35.82 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/pt/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.53 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/ro/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.62 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/sk/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.89 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/sl/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (35.25 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/fi/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (36.26 KB - PDF)

**First published:**

19/12/2019

**Last updated:**

31/08/2022

[View](/sv/documents/all-authorised-presentations/spravato-epar-all-authorised-presentations_sv.pdf)

Spravato : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (62.69 KB - PDF)

**First published:** 08/03/2021

[View](/en/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (24)](#file-language-dropdown-733)

български (BG) (59.68 KB - PDF)

**First published:**

08/03/2021

[View](/bg/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (61.62 KB - PDF)

**First published:**

08/03/2021

[View](/es/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (59.69 KB - PDF)

**First published:**

08/03/2021

[View](/cs/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (59.41 KB - PDF)

**First published:**

08/03/2021

[View](/da/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (65.05 KB - PDF)

**First published:**

08/03/2021

[View](/de/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (57.65 KB - PDF)

**First published:**

08/03/2021

[View](/et/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (50.11 KB - PDF)

**First published:**

08/03/2021

[View](/el/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (61.8 KB - PDF)

**First published:**

08/03/2021

[View](/fr/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

hrvatski (HR) (56.02 KB - PDF)

**First published:**

08/03/2021

[View](/hr/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_hr.pdf)

íslenska (IS) (57.27 KB - PDF)

**First published:**

08/03/2021

[View](/is/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (60.65 KB - PDF)

**First published:**

08/03/2021

[View](/it/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (59.33 KB - PDF)

**First published:**

08/03/2021

[View](/lv/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (60.99 KB - PDF)

**First published:**

08/03/2021

[View](/lt/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (60.33 KB - PDF)

**First published:**

08/03/2021

[View](/hu/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (79.11 KB - PDF)

**First published:**

08/03/2021

[View](/mt/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (62.74 KB - PDF)

**First published:**

08/03/2021

[View](/nl/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (57.48 KB - PDF)

**First published:**

08/03/2021

[View](/no/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (72.93 KB - PDF)

**First published:**

08/03/2021

[View](/pl/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (62.29 KB - PDF)

**First published:**

08/03/2021

[View](/pt/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (62.37 KB - PDF)

**First published:**

08/03/2021

[View](/ro/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (62.28 KB - PDF)

**First published:**

08/03/2021

[View](/sk/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (57.72 KB - PDF)

**First published:**

08/03/2021

[View](/sl/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (53.49 KB - PDF)

**First published:**

08/03/2021

[View](/fi/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (57.01 KB - PDF)

**First published:**

08/03/2021

[View](/sv/documents/conditions-member-states/spravato-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Spravato Active substance esketamine hydrochloride International non-proprietary name (INN) or common name esketamine Therapeutic area (MeSH) Depressive Disorder Anatomical therapeutic chemical (ATC) code N06AX27

### Pharmacotherapeutic group

Other antidepressants

### Therapeutic indication

Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.

## Authorisation details

EMA product number EMEA/H/C/004535 Marketing authorisation holder

Janssen-Cilag International NV

Turnhoutseweg 30

Opinion adopted 17/10/2019 Marketing authorisation issued 18/12/2019 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Spravato : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (196.83 KB - PDF)

**First published:** 29/10/2020

**Last updated:** 10/09/2025

[View](/en/documents/procedural-steps-after/spravato-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Spravato-H-C-PSUSA-00010825-202403 : EPAR - Scientific Conclusion

Adopted

Reference Number: EMA/552364/2024

English (EN) (130.97 KB - PDF)

**First published:** 23/01/2025

[View](/en/documents/scientific-conclusion/spravato-h-c-psusa-00010825-202403-epar-scientific-conclusion_en.pdf)

Spravato-H-C-004535-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/532169/2023

English (EN) (1.12 MB - PDF)

**First published:** 07/02/2024

[View](/en/documents/variation-report/spravato-h-c-004535-p46-005-epar-assessment-report_en.pdf)

Spravato-H-C-PSUSA-00010825-202203 : EPAR - Scientific Conclusion

Adopted

Reference Number: EMA/97281/2023

English (EN) (116.87 KB - PDF)

**First published:** 01/03/2023

[View](/en/documents/scientific-conclusion/spravato-h-c-psusa-00010825-202203-epar-scientific-conclusion_en.pdf)

Spravato-H-C-4535-II-0001-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/141382/2021

English (EN) (3.32 MB - PDF)

**First published:** 08/03/2021

[View](/en/documents/variation-report/spravato-h-c-4535-ii-0001-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Spravato (II-0001-G)

Adopted

Reference Number: EMA/CHMP/654550/2020

English (EN) (132.48 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-spravato-ii-0001-g_en.pdf)

## Initial marketing authorisation documents

Spravato : EPAR - Public assessment report

Adopted

Reference Number: EMA/614876/2019

English (EN) (3.37 MB - PDF)

**First published:** 19/12/2019

[View](/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Spravato

Adopted

Reference Number: EMA/557804/2019

English (EN) (69.11 KB - PDF)

**First published:** 18/10/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-spravato_en.pdf-0)

#### News on Spravato

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019) 18/10/2019

#### More information on Spravato

- [EMEA-001428-PIP03-15-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001428-pip03-15-m02)
- [Implementation of controlled access to and distribution of medicinal products in European Union (CONTROL-EU) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000313)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 10/09/2025

## Share this page

[Back to top](#main-content)